The offering raised net proceeds of $6.2 million, which will be used for working capital and general corporate purposes, the firm said.
The results also suggest the cfDNA assay has high sensitivity and 100 percent specificity, comparable to other technologies being developed for liquid biopsy testing.
Tests in development for the Alere q include HIV, tuberculosis, and Ebola assays, and it will initially be targeted to low-resource settings in the developing world.
The Singapore-based molecular diagnostics firm continues to operate under court supervision while its finances get sorted out.
The firm, which went public in October, made a public offering of more than 2.5 million units at $8.80 per unit.
In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.
A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.
Researchers report that paternally inherited genes are more likely to be expressed in mice.
National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.